[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641850":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":153,"collaborators":19,"id":155,"slug":156,"hasResults":157,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":19,"eligibilityCriteria":161,"healthyVolunteers":157,"sex":162,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":19,"studyType":168,"phases":169,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":72,"whyStopped":19,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"LY3439539","EXPERIMENTAL","LY3439539 administered intravenously (IV)",[13],"Drug: LY3439539",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered IV",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":31,"role":27,"phone":19,"phoneExt":19,"email":32},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[34,54,70,85,99,108,122,138],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Irvine Clinical Research","NOT_YET_RECRUITING","Irvine","California","92614","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-117.82311,33.66946,{"lat":46,"lon":45},[49,51],{"name":19,"role":27,"phone":50,"phoneExt":19,"email":19},"949-753-1663",{"name":52,"role":53,"phone":19,"phoneExt":19,"email":19},"Elly Lee","PRINCIPAL_INVESTIGATOR",{"facility":55,"status":36,"city":56,"state":19,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Flinders Medical Centre","Adelaide","5042","Australia","AU",{"type":43,"coordinates":61},[62,63],138.59863,-34.92866,{"lat":63,"lon":62},[66,68],{"name":19,"role":27,"phone":67,"phoneExt":19,"email":19},"+61 482 130 622",{"name":69,"role":53,"phone":19,"phoneExt":19,"email":19},"Lauren Priest",{"facility":71,"status":72,"city":73,"state":19,"zip":74,"country":58,"countryCode":59,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Austin Health - Heidelberg Repatriation Hospital","RECRUITING","Ivanhoe","3079",{"type":43,"coordinates":76},[77,78],145.04308,-37.76903,{"lat":78,"lon":77},[81,83],{"name":19,"role":27,"phone":82,"phoneExt":19,"email":19},"+613 9496 2388",{"name":84,"role":53,"phone":19,"phoneExt":19,"email":19},"Paul Yates",{"facility":86,"status":72,"city":87,"state":19,"zip":88,"country":58,"countryCode":59,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Southern Neurology","Kogarah","2217",{"type":43,"coordinates":90},[91,92],151.13564,-33.9681,{"lat":92,"lon":91},[95,97],{"name":19,"role":27,"phone":96,"phoneExt":19,"email":19},"+612 8566 1500",{"name":98,"role":53,"phone":19,"phoneExt":19,"email":19},"Raymond Schwartz",{"facility":100,"status":72,"city":101,"state":19,"zip":102,"country":58,"countryCode":59,"cosmosGeoPoint":19,"geoPoint":19,"contacts":103},"Macquarie University Hospital","Macquarie University","2109",[104,106],{"name":19,"role":27,"phone":105,"phoneExt":19,"email":19},"0298122956",{"name":107,"role":53,"phone":19,"phoneExt":19,"email":19},"James Burrell",{"facility":109,"status":72,"city":110,"state":19,"zip":111,"country":58,"countryCode":59,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"The Alfred","Melbourne","3004",{"type":43,"coordinates":113},[114,115],144.96332,-37.814,{"lat":115,"lon":114},[118,120],{"name":19,"role":27,"phone":119,"phoneExt":19,"email":19},"0437 498 365",{"name":121,"role":53,"phone":19,"phoneExt":19,"email":19},"David Darby",{"facility":123,"status":36,"city":124,"state":19,"zip":125,"country":126,"countryCode":127,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Christchurch Neurology Trials","Christchurch","8011","New Zealand","NZ",{"type":43,"coordinates":129},[130,131],172.63333,-43.53333,{"lat":131,"lon":130},[134,136],{"name":19,"role":27,"phone":135,"phoneExt":19,"email":19},"+ 64 33786662",{"name":137,"role":53,"phone":19,"phoneExt":19,"email":19},"Timothy Anderson",{"facility":139,"status":72,"city":140,"state":19,"zip":141,"country":140,"countryCode":142,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Lilly Centre for Clinical Pharmacology","Singapore","138623","SG",{"type":43,"coordinates":144},[145,146],103.85007,1.28967,{"lat":146,"lon":145},[149,151],{"name":19,"role":27,"phone":150,"phoneExt":19,"email":19},"+65 6413 9811",{"name":152,"role":53,"phone":19,"phoneExt":19,"email":19},"Jeffer Hann Wei Pang",{"type":154,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100641850","phase-1-a-study-of-ly3439539-in-participants-with-alzheimers-disease-100641850",false,"NCT07598370","A Study of LY3439539 in Participants With Alzheimer's Disease","A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Following Treatment With LY3439539 in Participants With Symptomatic Alzheimer's Disease","Inclusion Criteria:\n\n* Have gradual and progressive change in memory function reported by the participant or informant for 6 months or longer consistent with a diagnosis of dementia due to Alzheimer's disease\n* Have a Mini Mental Score Examination score of 16 to 24, inclusive\n* Meet plasma pTau criteria, as defined by the sponsor\n* Have body mass index within the range of 17 and 32 kilograms per square meter (kg\u002Fm²) (inclusive) at screening\n* Are women not of childbearing potential and men willing to practice effective contraception throughout the study.\n* Have adequate premorbid literacy, vision, and hearing throughout the study duration and able to complete study procedures.\n* Have at least 1, and up to 2, study partners who are in frequent contact with the participant (defined as at least 10 hours per week).\n\nExclusion Criteria:\n\n* Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants\u002Fcardiac pacemaker.\n* Have a screening MRI that shows evidence of significant abnormality.\n* Have history of suicidal behavior, or a lifetime history of suicide attempt or acute suicidality.\n* Have a history of\n\n  * Severe or ongoing allergy or hypersensitivity reactions\n  * Hypersensitivity to immunizations or immunoglobulins\n  * Two or more clinically significant or severe drug allergies,\n  * Intolerance to topical corticosteroids or severe posttreatment hypersensitivity reactions\n* Have current serious or unstable illnesses, including hepatic, renal, gastroenterological, respiratory, cardiovascular, neurologic (other than AD), psychiatric, endocrinologic, immunologic, hematologic disease, or other conditions\n* Require treatment with another monoclonal antibody or have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.\n* Have criteria that would preclude a lumbar puncture (LP).\n* Are currently enrolled in a clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study.\n* Have a current exposure to amyloid-targeting therapies (ATTs). Prior exposure to ATTs greater than 1 year from the last dose may be permitted at the discretion of the investigator and in consultation with the sponsor.","ALL","50 Years","85 Years",{"count":166,"type":167},30,"ESTIMATED","INTERVENTIONAL",[170],"PHASE1","The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease.\n\nParticipation in the study will last approximately 9 months with visits about once a month.",[173],"Alzheimer Disease",[175,176,177],"Cognitive Impairment","Neurodegenerative Diseases","Dementia","2026-08-06",{"date":180,"type":181},"2026-08-07","ACTUAL",{"date":183,"type":181},"2026-05-21",{"date":185,"type":167},"2027-08",{"name":5,"class":6},8]